Starpharma Holdings Limited

OTC Markets Group recently launched the OTCQX Composite Index (.OTCQX), OTCQX International Index (.OTCQXINT) and OTCQX U.S. Index (.OTCQXUS), to provide investors with a benchmark of the established, global and growth companies traded on the OTCQX marketplace.

Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.

The Board of Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY).

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced a successful capital raising of at least A$4.3 million and up to A$4.6 million, through a private placement to existing and new institutional and sophisticated investors.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the completion of patient testing in a clinical trial of VivaGel(R) that explores the length of time the antiviral activity of VivaGel remains following application.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention.

Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008

Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.